Avistone Biotechnology
Avistone Biotechnology is an oncology company focused on developing innovative therapies for patients with significant unmet medical needs globally. Their lead asset is PLB1001 (Vebreltinib), a small-molecule inhibitor targeting MET tyrosine kinase activity, recently approved in China. The company also has a pipeline of targeted therapies, including PLB1004.
Funding Round: Series B
Funding Amount: $140M
Date: 04-Jan-2024
Investors: SDIC CS Capital, IDG Capital, Yanchuang Capital, Cathay Capital, Bain Capital
Markets: Biotechnology Research, Precision Lung Cancer Treatments, Oncology, Pharmaceutical
HQ: Beijing, Beijing, China
Founded:
Website: https://en.avistonebio.com/
LinkedIn: https://www.linkedin.com/company/avistone-biotechnology-co-inc
Crunchbase: https://www.crunchbase.com/organization/avistone-llc
Leave a Comment
Comments
No comments yet.